bupropion hydrochloride; naltrexone hydrochloride · Azurity · NDA 200063
Contrave
Earliest generic entry, as listed
2 Jul 2034
Blocked by patent: US 10231964, US 10828294, US 10835527, US 11998542. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 18 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10231964 | use U-1583 | 2 Jul 2034 |
| US 10828294 | use U-1583 | 2 Jul 2034 |
| US 10835527 | use U-1583 | 2 Jul 2034 |
| US 11998542 | use U-1583 | 2 Jul 2034 |
| US 9633575 | use U-1583 | 25 Jun 2033 |
| US 10403170 | use U-1583 | 5 Jun 2033 |
| US 11139056 | use U-1583 | 5 Jun 2033 |
| US 9248123 | use U-1808 | 13 Jan 2032 |
| US 11033543 | use U-1583 | 10 Jan 2031 |
| US 8916195 | use U-1639 | 2 Feb 2030 |
| US 11324741 | use U-1583 | 29 May 2029 |
| US 8088786 | product | 3 Feb 2029 |
| US 10307376 | use U-1585 | 8 Nov 2027 |
| US 12048769 | use U-1585 | 8 Nov 2027 |
| US 8318788 | use U-1584 | 8 Nov 2027 |
| US 8722085 | use U-1585 | 8 Nov 2027 |
| US 9125868 | use U-1585 | 8 Nov 2027 |
| US 9107837 | use U-1639 | 4 Jun 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 200063 · 001 · RLD | tablet, extended release, oral | 90MG;8MG | 2 Jul 2034 |